NFE2L2 and cancer: Gain-of-function mutations in NFE2L2, loss-of-function mutations in key members of the KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex, and succination of KEAP1 have proven to activate the NRF2 pathway in many cancer types [14].